Search Results

Advanced Development of Additive Manufacturing ( A.D.A.M. ), a provider of 3D printing systems for customized bone implants, and the Icahn School of Medicine at Mount Sinai , in New York, NY , a renowned educational and health institution, have established a collaboration, which aims to enhance healthcare by innovating in bone implant delivery and soft tissue medical device development.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the closing of its license agreements with the Icahn School of Medicine at Mount Sinai, in New York, NY, to develop and commercialize electrocardiographic AI algorithms and assets.

Caris Life Sciences® announced that the Icahn School of Medicine at Mount Sinai, in New York, NY, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.

Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai recently announced the creation of the Center for Engineering and Precision Medicine, one of the first centers in the nation to bridge engineering and engineering science with medicine.

In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.

Icahn Mount Sinai and BioMark have agreed to explore multiple areas of collaboration as they share a mutual interest in researching, developing, and commercializing an integrative “multiomics” test for early detection and management of cancer following a successful outcome of this study.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), and the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), announced they have entered into a new research collaboration as part of HTG’s Transcriptome Panel Early Adopter Program.

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity from taking control of the company to the detriment of other shareholders.

Landos Biopharma, Inc. announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease.